-
April 18, 2012
The US Supreme Court has once again reversed the Federal Circuit in a case some hope may result in the Food and Drug Administration clarifying its guidelines on use codes filed with new drug applications
-
March 19, 2012
The High Court in London has granted an interim injunction against Teva to stop it launching a generic version of efavirenz, even though Teva had done nothing more than get market authorisation
-
March 19, 2012
A senior figure within India’s generic drugs industry says that more domestic companies are waiting to file applications for compulsory licences over patented pharmaceuticals
-
March 12, 2012
Today India has granted its first compulsory licence over a drug. But what of other countries that have used the IP system to make it easier for patients to access medicines?
-
March 12, 2012
In one of his final tasks before leaving the job, the outgoing head of India’s patent office has issued the country’s first compulsory licence over a drug since India began protecting pharmaceutical products seven years ago
-
March 12, 2012
India’s Controller of Patents has issued a compulsory licence over a cancer-treating drug, sorafenib, whose patent is held by Bayer
-
March 01, 2012
As patent owners in the personalised medicine sector wait to see if the Supreme Court will hear the Myriad gene patent case, other industries are bracing themselves for unintended consequences
-
March 01, 2012
The Supreme Court was set to decide whether to grant the Association for Molecular Pathology’s petition to hear its gene patent case against Myriad last Monday, but Mayo v Prometheus could be holding things up
-
February 15, 2012
The FDA’s draft guidance for biosimilars has provided some clarity for biosimilar applicants and innovator biologic companies. But lawyers say many questions remain
-
February 13, 2012
The latest round of negotations between the EU and India over a free-trade agreement was disrupted by protests over the way the IP clauses in the deal could affect access to medicines in developing countries
-
January 31, 2012
As more blockbuster drugs tumble off the patent cliff this year, the generic industry is set to become more profitable than ever - but the spike in competition means generics may also have to become more brand-savvy
-
January 20, 2012
A new law has come into force in France that will allow generic drugs companies to copy the colour and shape of drugs made by branded pharmaceutical companies
-
December 12, 2011
The Association for Molecular Pathology has asked the US Supreme Court to consider whether isolated DNA sequences are patentable under US law
-
December 12, 2011
The questions asked by the Supreme Court last week in Mayo v Prometheus have led to speculation that the justices might disagree with the Federal Circuit’s application of last year’s ruling in Bilski v Kappos to this case
-
November 25, 2011
The Australian government has rejected a ban on gene patents but proposed adding an ethical test to the Patents Act that could cause IP owners some headaches
-
November 11, 2011
Mayo Clinic is not asking the US Supreme Court for an “exotic” application of Section 101, and the personalised medicine industry will be fine without patents like that owned by Prometheus, the company’s counsel told Managing IP on Thursday
-
November 11, 2011
With just one month to go before they present their arguments to the judges of the highest US court, the parties in Mayo v Prometheus have filed their briefs and interested parties are also making their views known
-
November 07, 2011
“Despite the fact that we may have the utmost confidence in your patent estate, just settle.” That was how one investor advised IP counsel in the pharmaceutical and biotech industries
-
November 02, 2011
Patent offices in Europe are considering whether to change their approach to the patenting of stem cell-related inventions following a Court of Justice ruling last month
-
October 27, 2011
The owner of a plant variety right can bring an infringement action against a third party that has obtained material from a licensee, if the licensee has contravened the licence “to the extent that the conditions or limitations in question relate directly to the essential features of the Community plant variety right concerned”